You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Pep2m, myristoylated
Pep2m, myristoylated is a cell-permeable, myristoylated form of pep2m (Cat. No. 1595). Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces postsynaptic currents in CA1 neurons, AMPA-mediated currents in cultured hippocampal neurons and AMPA receptor surface expression.
Technical Data for Pep2m, myristoylated
(Modifications: Lys-1 = N-terminal Myr)
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Pep2m, myristoylated
|Solubility||Soluble to 1 mg/ml in water|
Product Datasheets for Pep2m, myristoylated
References for Pep2m, myristoylated
References are publications that support the biological activity of the product.
Nishimune et al (1998) NSF binding to GluR2 regulates synaptic transmission. Neuron 21 87 PMID: 9697854
Noel et al (1999) Surface expression of AMPA receptors in hippocampal neurons is regulated by an NSF-dependent mechanism. Neuron 23 365 PMID: 10399941
Luthi et al (1999) Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF-GluR2 interaction. Neuron 24 389 PMID: 10571232
Luscher et al (1999) Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron 24 649 PMID: 10595516
Yao et al (2008) PKMz maintains late long-term potentiation by N-ethylmaleimide-sensitive factor/GluR2-dependent trafficking of postsynaptic AMPA receptors. J.Neurosci. 28 7820 PMID: 18667614
If you know of a relevant reference for Pep2m, myristoylated, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Pep2m, myristoylated, Pep2m, myristoylated supplier, Peptide, inhibitors, inhibits, GluR2, subunit, binding, NSF, N-ethylmaleimide-sensitive, fusion, protein, Reduces, AMPA, currents, Glutamate, Receptors, iGlur, Ionotropic, GluA2, myr-pep2m, 3801, Tocris Bioscience
Citations for Pep2m, myristoylated
Citations are publications that use Tocris products.
Currently there are no citations for Pep2m, myristoylated. Do you know of a great paper that uses Pep2m, myristoylated from Tocris? Please let us know.
Reviews for Pep2m, myristoylated
There are currently no reviews for this product. Be the first to review Pep2m, myristoylated and earn rewards!
Have you used Pep2m, myristoylated?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.